Clinical characteristics, staging and treatment of patients with hepatocellular carcinoma in clinical practice. Prospective study of 136 patients

被引:1
|
作者
Gomez Rodriguez, Rafael [1 ]
Romero Gutierrez, Marta [1 ]
Gonzalez de Frutos, Concepcion [1 ]
de Artaza Varasa, Tomas [1 ]
de la Cruz Perez, Gema [1 ]
Ciampi Dopazo, Juan Jose [2 ]
Lanciego Perez, Carlos [2 ]
Gomez Moreno, Ana Zaida [2 ]
机构
[1] Complejo Hosp Toledo, Serv Aparato Digestivo, Toledo, Spain
[2] Complejo Hosp Toledo, Serv Radiol Intervencionista, Toledo, Spain
来源
GASTROENTEROLOGIA Y HEPATOLOGIA | 2011年 / 34卷 / 08期
关键词
Hepatocellular carcinoma; Surveillance; BCLC staging; Treatment; RANDOMIZED CONTROLLED-TRIAL; CHRONIC LIVER-DISEASE; PERCUTANEOUS RADIOFREQUENCY ABLATION; ALPHA-FETOPROTEIN; ETHANOL INJECTION; DIABETES INCREASES; NATURAL-HISTORY; UNITED-STATES; RISK-FACTORS; CIRRHOSIS;
D O I
10.1016/j.gastrohep.2011.06.009
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatocellular carcinoma (HCC) is the most frequent cause of mortality in patients with liver cirrhosis. There are no prospective series from a single tertiary hospital in Spain. Material and Methods: We performed a prospective study of patients with HCC in our center. Clinical and epidemiological characteristics, diagnostic method, staging according to the Barcelona Clinic Liver Cancer (BCLC) system and treatment were analyzed. Results: A total of 136 patients were included (80.9% men). The mean age was 66.62 +/- 11.68 years and 91.2% were cirrhotic. Hepatitis C virus (HCV) was the leading cause of liver disease (38.97%). The suspected diagnosis was established by a surveillance program in 63.2%. Noninvasive American Association criteria for the Study of Liver Diseases (AASLD) were the main diagnostic method (73.5%). According to the BCLC, 58.1% were in the early stage (0-A), 21.3% in stage B, 12.5% in stage C and 8.1% in stage D. Early stage patients had followed a surveillance program more frequently than those with non-early stages (79.75% versus 44.35%, p < 0.001). Potentially curative initial treatment was used in 45.58%, the most common treatment being percutaneous ethanol injection (23.13%). Conclusions: Most patients with HCC in our hospital have cirrhosis, the most frequent cause being HCV. HCC surveillance in at-risk patients could increase diagnosis of HCC at an early stage. We achieved an early diagnosis in more than half of cases. The most common initial treatment was percutaneous therapy. (C) 2011 Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:524 / 531
页数:8
相关论文
共 50 条
  • [21] Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice
    Di Costanzo, Giovan Giuseppe
    Tortora, Raffaella
    Iodice, Luca
    Lanza, Alfonso Galeota
    Lampasi, Filippo
    Tartaglione, Maria Teresa
    Picciotto, Francesco Paolo
    Mattera, Silvana
    De Luca, Massimo
    DIGESTIVE AND LIVER DISEASE, 2012, 44 (09) : 788 - 792
  • [22] Percutaneous ablation of hepatocellular carcinoma in older patients in clinical practice
    Romero Gutierrez, Marta
    Ruano Diaz, Lucia
    Munoz Lopez, Diego
    Artaza Varasa, Tomas
    Gonzalez de Frutos, Concepcion
    Sanchez Ruano, Juan Jose
    de la Cruz Perez, Gema
    Gomez Rodriguez, Rafael
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2015, 38 (02): : 54 - 61
  • [23] THE EFFECT OF ETELCALCETIDE IN HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM IN DAILY CLINICAL PRACTICE. A PROSPECTIVE MULTICENTER STUDY
    Molina, Pablo
    Yugueros, Alejandra
    Martin, Javier
    Perez-Baylach, Carmen M.
    Vizcaino, Belen
    Gonzalez-Moya, Mercedes
    Beltran, Sandra
    Kanter, Julia
    Bernat, Amparo
    Pallardo, Luis M.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34
  • [24] Eptifibatide in patients with percutaneous coronary intervention in clinical practice. Results of a prospective registry
    Zeymer, U
    Zahn, R
    Siegler, KE
    Senges, J
    HERZ, 2004, 29 (07) : 651 - 655
  • [25] Clinical characteristics and prognosis of hepatocellular carcinoma patients with paraneoplastic syndromes
    Luo, JC
    Hwang, SJ
    Wu, JC
    Lai, CR
    Li, CP
    Chang, FY
    Chiang, JH
    Lui, WY
    Chu, CW
    Lee, SD
    HEPATO-GASTROENTEROLOGY, 2002, 49 (47) : 1315 - 1319
  • [26] Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma
    Christian Rabe
    Tillmann Pilz
    Christoph Klostermann
    Marc Berna
    Hans H.Schild
    Tilman Sauerbruch
    Wolfgang H.Caselmann
    World Journal of Gastroenterology, 2001, (02) : 208 - 215
  • [27] Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma
    Rabe, C
    Pilz, T
    Klostermann, C
    Berna, M
    Schild, HH
    Sauerbruch, T
    Caselmann, WH
    WORLD JOURNAL OF GASTROENTEROLOGY, 2001, 7 (02) : 208 - 215
  • [28] Clinical Characteristics of Patients with Hepatocellular Carcinoma in a Middle Eastern Population
    Alswat, Khalid A.
    Sanai, Faisal M.
    Altuwaijri, Mansour
    Albenmousa, Ali
    Almadi, Majid
    Al-Hamoudi, Waleed K.
    Abdo, Ayman A.
    HEPATITIS MONTHLY, 2013, 13 (05)
  • [29] EDUCATIONAL PROGRAMS FOR PATIENTS WITH OSTEOPOROSIS IN CLINICAL PRACTICE.
    Myasoutova, L.
    Vasiliev, A.
    Lapshina, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 1036 - 1037
  • [30] Clinical Characteristics and Outcomes for Patients With Thymic Carcinoma Evaluation of Masaoka Staging
    Litvak, Anya M.
    Woo, Kaitlin
    Hayes, Sara
    Huang, James
    Rimner, Andreas
    Sima, Camelia S.
    Moreira, Andre L.
    Tsukazan, Maria
    Riely, Gregory J.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (12) : 1810 - 1815